SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

Diabesity: New Trends in Management

Jefferson Health

K. Furlong

Therapeutic Options for Patients With Type 2 Diabetes Mellitus: Focu…

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

J. Shen

COVID-19 & Diabetes: How to Manage SGLT2, GLP-1 RAs, Metformin, ACE …

Robert Eckel

2021 ADA Highlights: Selecting Glucose Lowering Combinations for Typ…

Ralph DeFronzo

2020 Updates on Insulin Therapy: What Are the Current ADA Standards …

John Tayek

Diabetes Complications: Q&A / Panel Discussion

Practical Ways to Achieve Targets in Diabetes Care

T. Brusko, J. Buse, S. Garg, S. Nissen, M. Rewers

Diabetes Updates

Duke Health

T. Setji

SGLT2 Inhibitors: Not Just for Diabetics Anymore

Courage and Innovation Symposium: Heart Failure & Heart Transplantation

R. Lavelle, Pharmd

SGLT2 Inhibitors: Drugs for the Ages

UChicago Medicine

R. DeFronzo

SGLT2 Inhibitors and GLP-1 Receptor Agonists: Different Classes, Dif…

KDIGO

H. Lambers Heerspink

Cardiovascular and Kidney Outcomes With Glucose-Lowering Agents

Primary Care Education Consortium

J. Gavin Iii

What's New in the Medical Management of Diabetes? A 2024 Guidelines …

Keck School of Medicine of USC

A. Lampe Dominguez

2021 ADA Highlights: Landmark DAPA-CKD Trial in Kidney Disease: Exte…

David Wheeler

SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Have We Learned From …

Cardiometabolic Health Congress (CMHC)

R. Eckel

Primary Care in Chronic Kidney Disease: Insights from the KDIGO 2024…

KDIGO

M. Shlipak

ACC 2022: An Overview of SGLT2i and GLP1 RA Use in Cardiovascular Di…

ACC 2022 Conference Coverage

R. Eckel